Medical Oncology Board
The Specialty Boards and Advisory Committees aim to maintain a composition that reflects the diversity and complexity of the physician and patient populations that certification serves. They include both practicing physician members and public members representing interdisciplinary healthcare professionals, patients and caregivers.
Dr. Nair is the Physician-in-Chief of the Lehigh Valley Cancer Institute (LVCI) in Allentown, Pennsylvania, and leads the health network’s academic programs. Dr. Nair is the Medical Director of the LVCI membership in the Memorial Sloan Kettering Cancer Center Alliance and has practiced oncology in the community setting for 27 years. He is the initial holder of the Auxiliary of Lehigh Valley Hospital Endowed Chair in Cancer. He is also the Council Director to the ABIM Board of Directors. He is ABIM Board Certified in Internal Medicine and Medical Oncology.
With clinical expertise in melanoma, kidney cancer and immunotherapy, Dr. Nair’s focus is to provide the highest-quality cancer care, including standard and research treatments. He leads a variety of clinical trials at Lehigh Valley Health Network (LVHN) to provide leading-edge options to patients. He leads the high-dose interleukin-2 program at LVHN for advanced melanoma and kidney cancer. Dr. Nair started the hematology/oncology fellowship at LVHN and served as the initial Program Director.
Dr. Nair has been a site principal investigator in the National Cancer Institute (NCI) Cooperative Group Program for over 25 years and was the first Chair of the NCI Early Phase Central Institutional Review Board. He has been a site principal investigator of over 40 T-cell checkpoint inhibitor trials at LVCI.
Dr. Nair received his medical degree from Jefferson Medical College in Philadelphia. He completed his residency at Geisinger Medical Center in Danville, Pennsylvania, and his fellowship at the University of Pittsburgh.
As of May 2025, Dr. Nair reported the following external relationships:
Funding for clinical trial support accrual, paid to Lehigh Valley Health Network, from the following companies:
- Bristol-Myers Squibb, serving as local hospital principal investigator of multicenter immunotherapy clinical trial.
- Elicio Therapeutics, serving as local principal investigator of multicenter vaccine study in pancreatic cancer, subsite of Memorial Sloan Kettering.
- Strata Oncology, serving as local hospital principal investigator for genomic testing and clinical trials.
Dr. Nair is the Physician-in-Chief of the Lehigh Valley Cancer Institute (LVCI) in Allentown, Pennsylvania, and leads the health network’s academic programs. Dr. Nair is the Medical Director of the LVCI membership in the Memorial Sloan Kettering Cancer Center Alliance and has practiced oncology in the community setting for 27 years. He is the initial holder of the Auxiliary of Lehigh Valley Hospital Endowed Chair in Cancer. He is also the Council Director to the ABIM Board of Directors. He is ABIM Board Certified in Internal Medicine and Medical Oncology.
With clinical expertise in melanoma, kidney cancer and immunotherapy, Dr. Nair’s focus is to provide the highest-quality cancer care, including standard and research treatments. He leads a variety of clinical trials at Lehigh Valley Health Network (LVHN) to provide leading-edge options to patients. He leads the high-dose interleukin-2 program at LVHN for advanced melanoma and kidney cancer. Dr. Nair started the hematology/oncology fellowship at LVHN and served as the initial Program Director.
Dr. Nair has been a site principal investigator in the National Cancer Institute (NCI) Cooperative Group Program for over 25 years and was the first Chair of the NCI Early Phase Central Institutional Review Board. He has been a site principal investigator of over 40 T-cell checkpoint inhibitor trials at LVCI.
Dr. Nair received his medical degree from Jefferson Medical College in Philadelphia. He completed his residency at Geisinger Medical Center in Danville, Pennsylvania, and his fellowship at the University of Pittsburgh.
As of May 2025, Dr. Nair reported the following external relationships:
Funding for clinical trial support accrual, paid to Lehigh Valley Health Network, from the following companies:
- Bristol-Myers Squibb, serving as local hospital principal investigator of multicenter immunotherapy clinical trial.
- Elicio Therapeutics, serving as local principal investigator of multicenter vaccine study in pancreatic cancer, subsite of Memorial Sloan Kettering.
- Strata Oncology, serving as local hospital principal investigator for genomic testing and clinical trials.
Dr. Ellent is an internist, hematologist and medical oncologist at West Jefferson Medical Center in Marrero, Louisiana, and Assistant Program Director and Site Director for the Louisiana State University (LSU) Hematology and Oncology Fellowship. She is the primary investigator for several clinical trials in the LSU-LCMC Health Cancer Center and passionate about providing clinical trial options for her patients in the community setting, allowing them to get access to cutting edge treatments without having to leave their support system. She is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology.
Dr. Ellent received her medical degree at Louisiana State University Health Sciences Center New Orleans. She completed a residency at Ochsner Clinic Foundation (Ochsner Medical Center) in New Orleans, where she was also chief resident. She completed a fellowship at Louisiana State University in New Orleans, where she was also chief fellow.
As of April 2025, Dr. Ellent reported the no ongoing external relationships.
Dr. Ellent is an internist, hematologist and medical oncologist at West Jefferson Medical Center in Marrero, Louisiana, and Assistant Program Director and Site Director for the Louisiana State University (LSU) Hematology and Oncology Fellowship. She is the primary investigator for several clinical trials in the LSU-LCMC Health Cancer Center and passionate about providing clinical trial options for her patients in the community setting, allowing them to get access to cutting edge treatments without having to leave their support system. She is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology.
Dr. Ellent received her medical degree at Louisiana State University Health Sciences Center New Orleans. She completed a residency at Ochsner Clinic Foundation (Ochsner Medical Center) in New Orleans, where she was also chief resident. She completed a fellowship at Louisiana State University in New Orleans, where she was also chief fellow.
As of April 2025, Dr. Ellent reported the no ongoing external relationships.
Dr. Gradishar is the Deputy Director for the Clinical Network of the Lurie Cancer Center and oversees the coordination of clinical cancer services within Lurie Cancer Center’s affiliated network, working closely with the medical director for Oncology Services in the different regions of Northwestern Medicine. Dr. Gradishar is Chief of the Division of Hematology and Oncology in the Department of Medicine and the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine. He is also Director of Lurie Cancer Center’s Maggie Daley Center for Women’s Cancer Care, where he develops and implements clinical trials of new therapeutic approaches for breast cancer. He is ABIM Board Certified in Internal Medicine and Medical Oncology.
Dr. Gradishar has served as chair of the Lurie Cancer Center’s Lynn Sage Breast Cancer Symposium, a nationally recognized, four-day meeting for the practicing clinician, since its inception in 1998. His research focuses on the development of adjuvant therapies and novel therapeutics for the treatment of breast cancer.
A fellow of the American College of Physicians and the American Society of Clinical Oncology (ASCO), Dr. Gradishar is also a member of the American Association for Cancer Research and the American Federation for Clinical Research. He has held numerous leadership positions in ASCO, been a member of numerous study sections for funding agencies including the Department of Defense, the National Institutes of Health, the Komen Foundation and the American Cancer Society. He has served as a consultant to the FDA Oncology Drug Advisory Committee. He is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group. Dr. Gradishar is Chair of the National Comprehensive Cancer Network Breast Cancer Guideline Panel and a member of the Breast Cancer Prevention Panel. He was also appointed Chair of the Breast Cancer Working Group for the Moonshot 2020 Initiative, which spearheaded the development of novel therapeutics for the treatment of breast cancer.
Dr. Gradishar is a member of the editorial boards of The Journal of Clinical Oncology, Clinical Breast Cancer, Current Treatment Options in Cancer, The European Journal of Medical Oncology and Oncology, and Editor-in-Chief of NEJM Journal Watch: Oncology and Hematology.
Dr. Gradishar received his medical degree from the University of Illinois, Chicago. He completed his residency at the Michael Reese Medical Center and his fellowship at University of Chicago Hospitals.
As of May 2025, Dr. Gradishar reported no ongoing external relationships.
Dr. Gradishar is the Deputy Director for the Clinical Network of the Lurie Cancer Center and oversees the coordination of clinical cancer services within Lurie Cancer Center’s affiliated network, working closely with the medical director for Oncology Services in the different regions of Northwestern Medicine. Dr. Gradishar is Chief of the Division of Hematology and Oncology in the Department of Medicine and the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine. He is also Director of Lurie Cancer Center’s Maggie Daley Center for Women’s Cancer Care, where he develops and implements clinical trials of new therapeutic approaches for breast cancer. He is ABIM Board Certified in Internal Medicine and Medical Oncology.
Dr. Gradishar has served as chair of the Lurie Cancer Center’s Lynn Sage Breast Cancer Symposium, a nationally recognized, four-day meeting for the practicing clinician, since its inception in 1998. His research focuses on the development of adjuvant therapies and novel therapeutics for the treatment of breast cancer.
A fellow of the American College of Physicians and the American Society of Clinical Oncology (ASCO), Dr. Gradishar is also a member of the American Association for Cancer Research and the American Federation for Clinical Research. He has held numerous leadership positions in ASCO, been a member of numerous study sections for funding agencies including the Department of Defense, the National Institutes of Health, the Komen Foundation and the American Cancer Society. He has served as a consultant to the FDA Oncology Drug Advisory Committee. He is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group. Dr. Gradishar is Chair of the National Comprehensive Cancer Network Breast Cancer Guideline Panel and a member of the Breast Cancer Prevention Panel. He was also appointed Chair of the Breast Cancer Working Group for the Moonshot 2020 Initiative, which spearheaded the development of novel therapeutics for the treatment of breast cancer.
Dr. Gradishar is a member of the editorial boards of The Journal of Clinical Oncology, Clinical Breast Cancer, Current Treatment Options in Cancer, The European Journal of Medical Oncology and Oncology, and Editor-in-Chief of NEJM Journal Watch: Oncology and Hematology.
Dr. Gradishar received his medical degree from the University of Illinois, Chicago. He completed his residency at the Michael Reese Medical Center and his fellowship at University of Chicago Hospitals.
As of May 2025, Dr. Gradishar reported no ongoing external relationships.
Dr. Martin is a medical oncologist at the West Cancer Center and Research Institute in Memphis, Tennessee. Dr. Martin is interested in international medical education and has worked with the U.S. State Department, volunteer missions and the Fulbright Specialist Program on international projects. Currently, he is a Visiting Professor of the Department of Oncology and Medical Radiology, Tashkent State Dental Institute, Uzbekistan; Visiting Professor of Internal Medicine at B. P. Koirala Institute of Health Sciences in Dhuran, Nepal; and Volunteer Associate Professor of Medicine at the University of Tennessee Health Science Center, Memphis.
After graduating from the University of Tennessee, Dr. Martin completed his internship and residency at Duke University Medical Center in Durham, North Carolina. and trained in medical oncology at Washington University in St. Louis, Missouri. He is ABIM Board Certified in Medical Oncology.
As of June 2024, Dr. Martin reported no ongoing external relationships.
Dr. Martin is a medical oncologist at the West Cancer Center and Research Institute in Memphis, Tennessee. Dr. Martin is interested in international medical education and has worked with the U.S. State Department, volunteer missions and the Fulbright Specialist Program on international projects. Currently, he is a Visiting Professor of the Department of Oncology and Medical Radiology, Tashkent State Dental Institute, Uzbekistan; Visiting Professor of Internal Medicine at B. P. Koirala Institute of Health Sciences in Dhuran, Nepal; and Volunteer Associate Professor of Medicine at the University of Tennessee Health Science Center, Memphis.
After graduating from the University of Tennessee, Dr. Martin completed his internship and residency at Duke University Medical Center in Durham, North Carolina. and trained in medical oncology at Washington University in St. Louis, Missouri. He is ABIM Board Certified in Medical Oncology.
As of June 2024, Dr. Martin reported no ongoing external relationships.
Dr. Munster is Professor in Residence at the University of California, San Francisco, where she is also the Director of Early Phase Clinical Trials Program at the Helen Diller Family Comprehensive Cancer Center and Program Leader of Developmental Therapeutics. She is the co-Leader of the BRCA Center. Dr. Munster is ABIM Board Certified in Medical Oncology and is the Chair of the ABIM Medical Oncology Longitudinal Knowledge Assessment (LKA®) Approval Committee.
She served at Memorial Sloan Kettering Cancer Center as a faculty member in the breast cancer program before joining the Division of Breast Oncology and Experimental Therapeutics Program at Moffitt Cancer Center and Research Institute in Tampa, Florida. Dr. Munster led the group as the Scientific Director of Breast Research and Co-Chair of the Phase I Program at Moffitt for six years prior to joining the University of California, San Francisco.
Her basic laboratory research interests are in the areas of developing novel targeted therapy for the treatment of treatment resistant cancer and their integration into current treatment strategies. Dr. Munster's research interest involves basic research studies on epigenetic modification of DNA repair and therapy resistance. Her laboratory is involved in several projects testing histone deacetylase inhibitors HDAC inhibitors reverse hormone therapy resistance in breast cancer and to reengage the immune defense. Dr. Munster's clinical research interests are in the areas of early anti-tumor drug development with focus on drugs that target the mTOR, P13k pathways and the epigenetic regulation of immune response to therapy. In addition to her interest in drug development, Dr. Munster has a special interest in the germline cancer mutations.
Dr. Munster has published in numerous scientific journals and has given lectures on topics such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research.
Dr. Munster received her medical degree from the University of Bern in Switzerland, completed her residency in internal medicine at Indiana University Medical Center and an oncology/hematology fellowship at Memorial Sloan Kettering Cancer Center.
As of May 2025, Dr. Munster reported the following external relationships.
Service on a research-related advisory board for the following companies, with honoraria:
- Caris
- Catalent Pharma Solutions
- Merck
Dr. Munster earns domestic and international royalties regarding a healthcare-related patent from Alessa.
Dr. Munster is Professor in Residence at the University of California, San Francisco, where she is also the Director of Early Phase Clinical Trials Program at the Helen Diller Family Comprehensive Cancer Center and Program Leader of Developmental Therapeutics. She is the co-Leader of the BRCA Center. Dr. Munster is ABIM Board Certified in Medical Oncology and is the Chair of the ABIM Medical Oncology Longitudinal Knowledge Assessment (LKA®) Approval Committee.
She served at Memorial Sloan Kettering Cancer Center as a faculty member in the breast cancer program before joining the Division of Breast Oncology and Experimental Therapeutics Program at Moffitt Cancer Center and Research Institute in Tampa, Florida. Dr. Munster led the group as the Scientific Director of Breast Research and Co-Chair of the Phase I Program at Moffitt for six years prior to joining the University of California, San Francisco.
Her basic laboratory research interests are in the areas of developing novel targeted therapy for the treatment of treatment resistant cancer and their integration into current treatment strategies. Dr. Munster's research interest involves basic research studies on epigenetic modification of DNA repair and therapy resistance. Her laboratory is involved in several projects testing histone deacetylase inhibitors HDAC inhibitors reverse hormone therapy resistance in breast cancer and to reengage the immune defense. Dr. Munster's clinical research interests are in the areas of early anti-tumor drug development with focus on drugs that target the mTOR, P13k pathways and the epigenetic regulation of immune response to therapy. In addition to her interest in drug development, Dr. Munster has a special interest in the germline cancer mutations.
Dr. Munster has published in numerous scientific journals and has given lectures on topics such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research.
Dr. Munster received her medical degree from the University of Bern in Switzerland, completed her residency in internal medicine at Indiana University Medical Center and an oncology/hematology fellowship at Memorial Sloan Kettering Cancer Center.
As of May 2025, Dr. Munster reported the following external relationships.
Service on a research-related advisory board for the following companies, with honoraria:
- Caris
- Catalent Pharma Solutions
- Merck
Dr. Munster earns domestic and international royalties regarding a healthcare-related patent from Alessa.
Diagnosed with breast cancer at 38 and again at 47, Ms. Walker became a dedicated patient advocate, health educator and health equity activist, striving to be a voice for the voiceless and empowering diverse communities worldwide.
Ms. Walker serves as President of the Young Survival Coalition Board of Directors and Co-Chair of the Herbert Irving Comprehensive Cancer Center's Patient Family Advisory Council. Her committee memberships include the National Coalition for Cancer Survivorship Cancer Policy Advocacy Training Steering Committee, the Society of Integrative Oncology's Patient Advocate and Health Equity Committees and the Recruitment and Retention and Patient Advocate Committees of the National Cancer Institute’s SWOG [Southwest Oncology Group]. She facilitates support groups for women of African heritage with breast, ovarian or uterine cancer. Through SHARE Cancer Support's Side by Side Program, Ms. Walker trains medical students and doctors on delivering difficult news, emphasizing patient-doctor communication.
An accomplished speaker, Ms. Walker has been a moderator, panelist and discussant at numerous scientific conferences. She has appeared on ABC World News, NBC's TODAY Show, The Good Fight, Here and Now, and The Breakfast Club. Ms. Walker and her daughter, Shayna, were featured in SHAPE Magazine's "Breast Cancer: A Family Affair."
A graduate of the National Breast Cancer Coalition (NBCC) Project LEAD, Ms. Walker has participated in NBCC Hill Days and reviewed research for the U.S. Department of Defense's Congressionally Directed Medical Research Program’s Breast Cancer Research Program and the Patient-Centered Outcomes Research Institute. She collaborates with cancer researchers at Columbia University, the University of Wisconsin-Madison, HistoryMemorial Sloan Kettering Cancer Center and Weill Cornell Medicine.
Recognized for her volunteerism, community leadership and advocacy, Ms. Walker also enjoys spending time with family, baking gourmet bread pudding, traveling, performing arts and sporting events.
As of May 2025, Ms. Walker reported no ongoing external relationships.
Diagnosed with breast cancer at 38 and again at 47, Ms. Walker became a dedicated patient advocate, health educator and health equity activist, striving to be a voice for the voiceless and empowering diverse communities worldwide.
Ms. Walker serves as President of the Young Survival Coalition Board of Directors and Co-Chair of the Herbert Irving Comprehensive Cancer Center's Patient Family Advisory Council. Her committee memberships include the National Coalition for Cancer Survivorship Cancer Policy Advocacy Training Steering Committee, the Society of Integrative Oncology's Patient Advocate and Health Equity Committees and the Recruitment and Retention and Patient Advocate Committees of the National Cancer Institute’s SWOG [Southwest Oncology Group]. She facilitates support groups for women of African heritage with breast, ovarian or uterine cancer. Through SHARE Cancer Support's Side by Side Program, Ms. Walker trains medical students and doctors on delivering difficult news, emphasizing patient-doctor communication.
An accomplished speaker, Ms. Walker has been a moderator, panelist and discussant at numerous scientific conferences. She has appeared on ABC World News, NBC's TODAY Show, The Good Fight, Here and Now, and The Breakfast Club. Ms. Walker and her daughter, Shayna, were featured in SHAPE Magazine's "Breast Cancer: A Family Affair."
A graduate of the National Breast Cancer Coalition (NBCC) Project LEAD, Ms. Walker has participated in NBCC Hill Days and reviewed research for the U.S. Department of Defense's Congressionally Directed Medical Research Program’s Breast Cancer Research Program and the Patient-Centered Outcomes Research Institute. She collaborates with cancer researchers at Columbia University, the University of Wisconsin-Madison, HistoryMemorial Sloan Kettering Cancer Center and Weill Cornell Medicine.
Recognized for her volunteerism, community leadership and advocacy, Ms. Walker also enjoys spending time with family, baking gourmet bread pudding, traveling, performing arts and sporting events.
As of May 2025, Ms. Walker reported no ongoing external relationships.